The ECG and the Phenotypic Expression of HCM The ECG and the Phenotypic Expression of HCM
What is the significance of marked ECG abnormalities in an individual with a positive genotype for hypertrophic cardiomyopathy?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Continuous ECG Changes Over 8 Years in an Athlete With HCM Continuous ECG Changes Over 8 Years in an Athlete With HCM
This case report reveals that abnormal ECG findings may precede the symptoms and signs of hypertrophic cardiomyopathy for many years.Journal of Medical Case Reports (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 8, 2019 Category: Radiology Tags: Cardiology Journal Article Source Type: news
FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis
May 06, 2019 -- On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Treatments for Heart Failure Caused by Rare Disease
MONDAY, May 6, 2019 -- Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2019 Category: Pharmaceuticals Source Type: news
Two Drugs Approved for Cardiomyopathy Caused by Amyloidosis
Two different versions of tafamadis get the FDA ’s nod to treat a rare heart disease. (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Valerie DeBenedette Tags: Cardiology Cardiovascular Diseases Heart Health Latest e-News New Products The Latest Source Type: news
FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy
These are the first FDA-approved treatments for transthyretin-mediated amyloidosis cardiomyopathy, a rare and often fatal disease caused by deposition of amyloid fibrils in the myocardium.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Pfizer gets U.S. approval for $225,000 a year heart drug
The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said. (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ. (Source: World Pharma News)
Source: World Pharma News - May 6, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Takotsubo Cardiomyopathy After an Upper and Lower Endoscopy Takotsubo Cardiomyopathy After an Upper and Lower Endoscopy
This case presents management approaches which can be used when treating at-risk patients who have experienced symptoms of stress cardiomyopathy after undergoing endoscopy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
A promising new treatment for infants with Noonan syndrome
(University of Montreal) Infants less than six months old with Noonan Syndrome, hypertrophic cardiomyopathy and congestive heart failure normally have a poor prognosis, with a one-year survival rate of 34%. In the new study, doctors used Trametinib to try to treat NS in two patients.They observed dramatic improvement of clinical and cardiac status in the patients only three months after treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2019 Category: International Medicine & Public Health Source Type: news
Apr 19 2019 This Week in Cardiology Apr 19 2019 This Week in Cardiology
Anticoagulation for embolic stroke of unknown origin, added-sugar labels, AF-patient knowledge, LDL-C and hemorrhagic stroke, and genetic signals in cancer-care cardiomyopathy are discussed this week.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 19, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Genetic Crosstalk in Cancer Therapy-Induced Cardiomyopathy Genetic Crosstalk in Cancer Therapy-Induced Cardiomyopathy
A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
Genetic Crosstalk in Cancer-Therapy-Induced Cardiomyopathy Genetic Crosstalk in Cancer-Therapy-Induced Cardiomyopathy
A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 18, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Chagas Cardiomyopathy: The Disease You Might Not Think Of Chagas Cardiomyopathy: The Disease You Might Not Think Of
A growing public health threat demands more awareness of Chagas disease and its manifestations.Medscape Infectious Diseases (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 16, 2019 Category: Infectious Diseases Tags: Infectious Diseases Case Challenge Source Type: news
A new role for genetics in cancer therapy-induced cardiomyopathy
(Brigham and Women's Hospital) A team of investigators from Brigham and Women's Hospital and Harvard Medical School finds that genetics may be at play and elucidates rare genetic variants which may influence risk for developing cancer therapy-induced cardiomyopathy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 10, 2019 Category: International Medicine & Public Health Source Type: news
